IE
FATE icon

Israel Englander’s Fate Therapeutics FATE Stock Holding History

Israel Englander’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$175K – 6091
2024
Q3 		$175K Buy
+50,000
New +$195K ﹤0.01% 5480
2022
Q1 		– Sell
-10,000
Closed -$585K – 7066
2021
Q4 		$585K Buy
+10,000
New +$567K ﹤0.01% 4910
2021
Q2 		– Sell
-10,000
Closed -$825K – 6672
2021
Q1 		$825K Buy
+10,000
New +$958K ﹤0.01% 4393

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's FATE Position: Q2 2026 in Review

Israel Englander opened a new position in Fate Therapeutics (FATE) in Q2 2026: 2,433,978 shares worth $6.57M. The stake represents ﹤0.01% of the portfolio and ranks #2732 among its holdings. This is a return to the name: Israel Englander previously reported a position in FATE as recently as Q4 2025.

Israel Englander first reported a position in FATE in Q4 2013 and has held it in 40 quarters since. The position peaked at $52.1M in Q3 2019. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Israel Englander held 2,433,978 shares of Fate Therapeutics worth $6.57M as of Q2 2026.
  • Fate Therapeutics was a new Israel Englander position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2732 holding.
  • Israel Englander first reported a position in Fate Therapeutics in Q4 2013 and has held it in 40 quarters since.
  • Israel Englander's Fate Therapeutics position peaked at $52.1M in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.